Sleep apnea
Drug research and approvals for sleep apnea: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 330 studies of sleep apnea are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 330
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 1
- Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep ApneaNCT07921329 · Not applicable · E-DA Hospital · starts Jun 7, 2025
- Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and…NCT07923825 · Not reported · Fu Jen Catholic University · starts Mar 1, 2026
- Functional Capacity in Obstructive Sleep ApneaNCT07913139 · Not reported · Karabuk University · starts Oct 28, 2026
- Oura Ring OA15 ValidationNCT07908199 · Not reported · Ouraring Inc. · starts Aug 28, 2026
- Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive Sleep Apnea…NCT07908160 · Not reported · Peking University First Hospital · starts Aug 7, 2026
- Effect of Transcutaneous Electrical Stimulation on Polysomnographic Parameters in Patients With Obstructive Sleep ApneaNCT07891702 · Not applicable · Mansoura University · starts Jul 6, 2025
- Physical Activity, Sleep Quality, and Respiratory Function in Obstructive Sleep ApneaNCT07889154 · Not applicable · Medipol University · starts Oct 23, 2026
- Respiratory Progression in Adults With Duchenne Muscular Dystrophy.NCT07879989 · Not reported · Istituto Giannina Gaslini · starts Sep 9, 2025
- Effects of Surgery on Oral Frailty and Dysphagia in Patients With Obstructive Sleep ApneaNCT07880067 · Not reported · National Sun Yat-sen University · starts Jun 12, 2026
How its trials ended
2,273 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 496 whose ending is known, 42% met their primary endpoint, 7% missed it and 51% stopped early.
- Completed, result not reported98944%
- Ongoing41818%
- Status unknown37016%
- Met its primary endpoint2089%
- Stopped: other or unclear1487%
- Stopped: enrollment or feasibility713%
- Missed its primary endpoint372%
- Stopped: lack of efficacy10<1%
- Stopped: funding9<1%
- Stopped: sponsor or business decision8<1%
- Stopped: safety5<1%
| Mar 6, 2026 | A master protocol for phase 3 randomized, double-blind, placebo-controlled studies to investigate the efficacy and safety of once weekly eloralintide in adult…Eloralintide (LY3841136) | Eli Lilly | Ongoing |
| Oct 24, 2025 | A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of maridebart cafraglutide in adult…Maridebart cafraglutide (amg 133) | Amgen | Ongoing |
| Jun 14, 2024 | A phase 3 open label continuation protocol of a fixed dose combination of aroxybutynin and atomoxetine (AD109) in obstructive sleep apneaAD109 (atomoxetine-aroxybutynin) | Apnimed | Ongoing |
| Nov 8, 2023 | Phase 3 randomized double-blind placebo-controlled 6-month parallel-arm study to compare a fixed dose combination of aroxybutynin/atomoxetine (AD109) to…Atomoxetine-aroxybutynin (AD109) | Apnimed | Closed |
| May 12, 2022 | Dexamethasone as a novel treatment for obstructive sleep apnea in childrenDexamethasone | The Hospital for Sick Children | Ongoing |
| Jun 18, 2021 | Solriamfetol's effect on cognitive health in apnea participants during a randomized placebo-controlled study (SHARP): a 5-week double-blind,…Solriamfetol (JZP-110) | Jazz Pharmaceuticals | Ongoing |
| Jul 3, 2019 | Combined treatment of angiotensin receptor blocker and antioxidant supplementaion as a novel adjunctive therapy for 24-hour blood pressure improvement in…Telmisartan / Alpha-lipoic acid | University of British Columbia, School of Health and Exercise Science | Pending |
| Jun 5, 2015 | A long-term, open-label, safety and maintenance of efficacy study of JZP-110 [(r)-2-AMINO-3-phenylpropylcarbamate hydrochloride] in the treatment of excessive…JZP-110 | Jazz Pharmaceuticals | Ongoing |
| May 20, 2015 | A twelve-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP-110…JZP-110 | Jazz Pharmaceuticals | Closed |
| Jun 3, 2013 | Cycloserine in the treatment of sleep apnea.Cycloserine | University of Manitoba | Pending |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 1, 2021 | OzawadePitolisant | Bioprojet Pharma | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA